Access
To read this story in full you will need to login or make a payment (see right).
News Feature
Nature 435, 138 (12 May 2005) | doi:10.1038/435138a; Published online 11 May 2005
Open Innovation Challenges
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
John Innes Centre Project Leader in Plant or Microbial Sciences
- University of East Anglia
- Norwich, NR4 7TJ, UK
Professor of Experimental Virology (W3)
- University Hospital Jena, Institute of Virology and Antivirale Therapy
- Jena, Germany
Chinese clinical trials: Consenting adults? Not necessarily...
David Cyranoski1
- David Cyranoski is Nature's Asian-Pacific correspondent.
Abstract
Companies and scientists in the West are keen to test their drugs in China, which is an important future market. But those running clinical trials need to be on their guard, says David Cyranoski.
In October 2003, China became the first country to move gene therapy into the medical mainstream, when it approved for general clinical use a treatment for head and neck squamous cancer. The feat was a symbol of the country's biomedical ambitions, and was lauded in the Chinese media.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Both a ?magic bullet? and good aim are required to link public health interests and health care needs in HIV infectionNature Medicine News and Views (01 Mar 2000)
